Bio-Tech company Cannabis Science Inc. recently announced that they are negotiating a deal to bring a cannabis-based anti-cancer drug to the market with the approval of the FDA.
Robert Melamede, Ph.D. and Cannabis Science CEO said, "We appreciate the dedication and patience that many of our investors have shown. We have been working diligently to provide a path in the complicated legal and regulatory environment that surrounds the medical cannabis industry that will benefit our shareholders and the countless people in need around the world who have been deprived of the health promoting benefits provided by this unique plant. These commercialization agreements will give us an opportunity to generate significant revenues for Cannabis Science We provide a further update and agreement details in the coming weeks as these commercial agreements are signed.”
According to information released by the company:
You can learn more about Cannabis Science Inc. at their Web site here.
According to information released by the company:
"Some of these new deals are designed to bring its anti-cancer cannabis formulations and its other critical ailment formulations to the public through the FDA in the USA and more rapidly through other expanded markets around the world."One of the larger deals the company expects to sign and announce within the next few days is a business relationship with a multi-million dollar pharmaceutical technology provider. Under the terms of the agreement, Cannabis Science will work closely with the technology provider to market and sell their co-branded products on an exclusive and non-exclusive basis with this new ground breaking technology in the Medical Cannabis industry.
You can learn more about Cannabis Science Inc. at their Web site here.
Comments
Post a Comment